SCHEMBL14724727

SCHEMBL14724727

CNC(=O)Cc1cccc(C(C)C)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.49
NLRP3 Q96P20 1/20 0.47
BCHE P06276 4/20 0.46
ACHE P22303 1/20 0.46
BACE1 P56817 2/20 0.43
ALDH1A1 P00352 2/20 0.42
MAPT P10636 2/20 0.42
HPGD P15428 2/20 0.42
RORC P51449 1/20 0.42
KDM4E B2RXH2 1/20 0.42
MDM4 O15151 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
TP53 P04637 1/20 0.42
CYP3A4 P08684 1/20 0.42
TYR P14679 1/20 0.42
ALOX15 P16050 1/20 0.42
ALOX12 P18054 1/20 0.42
CA5A P35218 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18608083 0.87 HDAC8 (0.55) CNR2NLRP3BCHEBACE1ALDH1A1
SCHEMBL18025556 0.84 RAB9A (0.51) CNR2BCHEACHEBACE1ALDH1A1
SCHEMBL26078961 0.83 HPGD (0.56) CNR2NLRP3BCHEBACE1ALDH1A1
SCHEMBL20376565 0.81 CNR2 (0.44) CNR2NLRP3BCHEBACE1ALDH1A1
SCHEMBL18608084 0.81 ADRB2 (0.48) CNR2NLRP3BCHE
SCHEMBL1261429 0.81 AKR1B1 (0.52) CNR2BCHEBACE1ALDH1A1MAPT
SCHEMBL12599734 0.81 HDAC4 (0.46) CNR2NLRP3BCHEBACE1ALDH1A1
SCHEMBL22783309 0.80 CNR2 (0.43) CNR2NLRP3BCHEBACE1ALDH1A1
SCHEMBL24500947 0.80 SLC7A5 (0.46) CNR2HDAC8
SCHEMBL8186958 0.80 SLC7A5 (0.56) CNR2BCHEBACE1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230135635-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME Sanford Burnham Prebys Medical Discovery Institute 2023-05-04 US disclosed
EP-1523473-B1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA (DE) 2013-02-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135635-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME ULK2, ULK1, ULK3 CNR2 3771/4885NLRP3 3136/4885BCHE 4186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.